Data science and AI have the potential to transform the discovery and development of medicines. However, there is a lot of hype surrounding AI. The session will cover: What has been achieved to date? What is realistic to expect from data science and AI in the next 5 to 10 years? How can data science experts manage expectations? How can pharma and tech better collaborate to realise the potential of data science and AI in healthcare?
The interdisciplinary panel will be chaired by Gareth Mitchell, presenter from the BBC's Digital Planet.
Anne is Chief Scientific Officer, Head of Preclinical Development and Site Head for the Benevolent Cambridge Laboratories. Anne is responsible for driving the early AI augmented discovery portfolio through Lead Optimisation to delivery of pre-clinical candidate drug molecules. Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stage development